

WELCOME MESSAGE

Dear colleagues and friends,

It is our great pleasure to invite you to the 6th edition of the EMN meeting – EMN2025 - taking place in the majestic and historic city of Athens from 10 to 12 April, 2025.

This event promises to be an unparalleled opportunity for learning, collaboration, and professional growth. With experts joining us from across Europe and beyond, the meeting offers a platform for deepening our understanding of multiple myeloma through a range of highly educational sessions. Designed to be particularly valuable for young hematologists and trialists, the meeting provides a unique chance to present research, share ideas, and engage in meaningful discussions with colleagues from around the world.

Highlights of the program include:

- Educational sessions accredited with EBAH credits, delivering cutting-edge knowledge and updates in the field.
- Several challenges in multiple myeloma, such as high-risk SMM and therapy.
- An in-depth discussion of the role of MRD and novel techniques in driving diagnosis and treatment decisions, and novel definition of high-risk disease.
- New EHA/EMN treatment guidelines, a highly valuable tool for clinicians in everyday practice.
- A special session with patient associations, fostering dialogue between clinicians, researchers, and taking into account patients' expectations and needs.
- Dedicated sessions with sponsors, showcasing the latest advancements and innovations in diagnostics and treatment.
- Interactive Meet the Experts sessions, offering smaller, focused discussions on specific topics, providing practical insights and lively exchanges.

This is a rare occasion to enhance your expertise in a uniquely enriching environment while immersing yourself in the timeless beauty and rich culture of Athens, with its iconic historical landmarks and vibrant modern life.

The Divani Caravel Hotel, the venue for EMN2025, is the ideal setting for hosting such a prestigious international event. It offers participants the perfect balance of convenience and comfort, enabling them to fully enjoy their stay in Athens.

Don't miss this opportunity to advance your knowledge, connect with peers, and immerse yourself in a truly memorable event.

We look forward to welcoming you to Athens for this extraordinary meeting!

Evangelos Terpos & Meletios Athanasios Dimopoulos - EMN2025 Local Organizers

Pieter Sonneveld & Mario Boccadoro - EMN President & Vicepresident

On behalf of the scientific organizers and program coordinators.

FACULTY

Frida Bugge	Askeland	Oslo, Norway	Hira	Mian	Hamilton, Canada
Meral	Beksac	Ankara, Turkey	Paolo	Milani	Pavia, Italy
Luca	Bertamini	Rotterdam, The Netherlands	Roberto	Mina	Turin, Italy
Mario	Boccardo	Turin, Italy	Joseph	Mikhael	Studio City, USA
Niccolò	Bolli	Milan, Italy	Mohamad	Mohty	Paris, France
Sara	Bringhen	Turin, Italy	Philippe	Moreau	Nantes Cedex, France
Annemiek	Broijl	Rotterdam, The Netherlands	Adrian	Mosquera Orgueira	Santiago De Compostela, Spain
Gabriele	Buda	Pisa, Italy	Pellegrino	Musto	Bari, Italy
Jo	Caers	Liege, Belgium	Ajay	Nooka	Atlanta, USA
Michele	Cavo	Bologna, Italy	Elizabeth	O'Donnel	Boston, USA
Yael	Cohen	Tel Aviv, Israel	Enrique Maria	Ocio San Miguel	Santander, Spain
Gordon	Cook	Leeds, United Kingdom	Albert	Oriol Rocafiguera	Barcelona, Spain
Thomas	Cupedo	Rotterdam, The Netherlands	Robert Z.	Orlowski	Houston, USA
Mattia	D'Agostino	Turin, Italy	Aurore	Perrot	Toulouse, France
Michel	Delforge	Leuven, Belgium	Noemi	Puig Moron	Valladolid, Spain
Sosanna	Delimpasi	Athens, Greece	Marc	Raab	Heidelberg, Germany
Meletios-Athanasios	Dimopoulos	Athens, Greece	Jakub	Radocha	Hradec Králové, Czech Republic
Christoph	Driessen	St. Gallen, Switzerland	Karthik	Ramasamy	Oxford, United Kingdom
Dominik	Dytfeld	Poznan, Poland	Fredrik Hellem	Schjesvold	Oslo, Norway
Hermann	Einsele	Würzburg, Germany	Stefan	Schönland	Heidelberg, Germany
Maria	Gavriatopoulou	Athens, Greece	Pieter	Sonneveld	Rotterdam, The Netherlands
Francesca Maria	Gay	Turin, Italy	Andrew	Spencer	Melbourne, Australia
Alessandro	Gozzetti	Siena, Italy	Alessandra	Tedeschi	Milan, Italy
Martin	Gramatzki	Kiel, Germany	Silene	ten Seldam	Edinburgh, UK
Roman	Hájek	Ostrava, Czech Republic	Evangelos	Terpos	Athens, Greece
Vania T.M.	Hungria	São Paulo, Brazil	Steven	Treon	Boston, USA
Arnaud	Jaccard	Limoges, France	Suzanne	Trudel	Toronto, Canada
Sundar	Jagannath	New York, USA	Saad Z.	Usmani	Charlotte, USA
Efstathios	Kastritis	Athens, Greece	Niels	van de Donk	Amsterdam, The Netherlands
Eirini	Katodritou	Thessaloniki, Greece	Ashutosh	Wechalekar	London, United Kingdom
Maria	Krauth	Wien, Austria	Katja Christina	Weisel	Hamburg, Germany
Xavier	Leleu	Poitiers Cedex, France	Ruth	Wester	Rotterdam, The Netherlands
Heinz	Ludwig	Wien, Austria	Kwee	Yong	London, United Kingdom
Salomon	Manier	Lille, France	Elena	Zamagni	Bologna, Italy
Joaquín	Martinez-Lopez	Madrid, Spain	Sonja	Zweegman	Amsterdam, The Netherlands
Maximilian	Merz	New York, USA			

TIMETABLE

Thursday, April 10, 2025	Friday, April 11, 2025	Saturday, April 12, 2025
	09.00 - 09.45 SESSION V NDMM - TRANSPLANT INELIGIBLE FIT PATIENTS	09.00 - 10.00 EDUCATIONAL SESSION XII HOT TOPICS RELEVANT FOR THE MANAGEMENT OF MYELOMA PATIENTS
	09.45 - 10.45 SESSION VI NDMM - TRANSPLANT INELIGIBLE UNFIT AND/OR FRAIL PATIENTS	10.00 - 11.00 EDUCATIONAL SESSION XIII EHA-EMN JOINT SESSION: UPDATE ON EHA/EMN CLINICAL GUIDELINES
09.45 - 10.00 OPENING CEREMONY	10.45 - 11.00 BREAK AND POSTER VIEWING	11.00 - 11.30 BREAK AND POSTER VIEWING
10.00 - 11.00 SESSION I HIGH-RISK SMM - WHEN TO START THERAPY?	11.00 - 11.30 SESSION VII RRMM - NON IMMUNOTHERAPY	11.30 - 12.45 SESSION XIV EMN HIGHLIGHT SESSION: CURRENT & UPCOMING TRIALS, AND FUTURE PERSPECTIVES
11.00 - 12.45 SESSION II NEW PROGNOSTIC FACTORS: MRD, CTCS, MASS SPEC, NEW DEFINITIONS OF HIGH RISK	11.30 - 12.30 SESSION VIII ANTI-BCMA TREATMENT & SEQUENCING	12.45 - 13.00 CONCLUSIONS AND FINAL GREETINGS
12.45 - 14.00 LUNCH AND MEET THE EXPERT SESSIONS	12.30 - 13.45 LUNCH AND MEET THE EXPERT SESSIONS	
14.00 - 15.30 BRISTOL MYERS SQUIBB SPONSORED SYMPOSIUM Innovations in multiple myeloma care: bridging gaps and navigating relapse challenges	13.45 - 15.15 JOHNSON AND JOHNSON SPONSORED SYMPOSIUM Let's get clinical! Novel strategies for optimising multiple myeloma care in 2025	
15.30 - 16.40 SESSION III MGCS & AMYLOIDOSIS	15.15 - 16.15 SESSION IX NOVEL TARGETS OF IMMUNOTHERAPY	
16.40 - 17.10 BREAK AND POSTER VIEWING	16.15 - 16.45 BREAK AND POSTER VIEWING	
17.10 - 18.40 SANOFI SPONSORED SYMPOSIUM The road to MRD negativity: how MRD is changing practice in NDMM	16.45 - 17.45 SPONSORED LECTURE SESSION LECTURE 1 BY MENARINI STEMLINE LECTURE 2 BY REGENERON	
18.40 - 19.40 SESSION IV NDMM - TRANSPLANT ELIGIBLE	17.45 - 18.30 SESSION X MANAGEMENT OF TOXICITIES OF NEW IMMUNOTHERAPIES IN THE CLINIC	
19.40 - 20.30 WELCOME COCKTAIL	18.30 - 19.00 SESSION XI PATIENT ASSOCIATIONS	

CONGRESS INFORMATION

VENUE

DIVANI CARAVEL HOTEL
2 Vassileos Alexandrou ave
16121 Athens, Greece
Ph +30 210 72 07 000
www.divanicaravelhotel.com

HOW TO REACH THE MEETING VENUE

The Divani Caravel Hotel offers easy access to the airport and the metro.

A) From Athens International Airport “Eleftherios Venizelos”:

By taxi:

There is a Taxi Station right outside the arrivals at airport. Ask the driver to get you to CARAVEL hotel. An average cost of the journey on normal traffic is 45 euros and is approx. 30-40 minutes drive

By car:

Exit the airport taking Attiki Odos highway following the signs Imittos ring. Exit right at the Katechaki / Mesogion av. Signs.

Where Katechaki meets Mesogion av. turn left and follow direction to Michalakopoulou av.

Driving down Michalakopoulou av. you will meet Hilton hotel on your right hand side.

At this point, make a left turn into Vas. Alexandrou av. and you will see DIVANI CARAVEL hotel around 100 meters away on number 2, Vas. Alexandrou av.

By public transport:

You take the BLUE line from the Airport. Get off the train at EVANGELISMOS Station. While in the station, take the left exit towards VAS. SOFIAS street.

Walk pass the Hilton hotel (on your left hand side), cross Michalakopoulou Street, continue straight on Vas. Alexandrou Street.

You will see DIVANI CARAVEL hotel on your right.

If you do not want to walk (approximately 5-7 minutes walk), you may take the 224 bus (the stop is across the metro station exit), and get off at “CARAVEL Bus Stop”, right in front of the hotel

B) From Larissis Train Station

By taxi:

There is a Taxi Station right outside the Train Station. Ask the driver to get you to CARAVEL hotel. An average cost of the journey on normal traffic is 20 euros and is approx. 20 minutes drive

By public transport:

There is a Metro station at Larissis Station. You take the RED line with direction to AGIOS DIMITRIOS. Change line at SYNTAGMA station and take the BLUE line with direction to Airport.

Get off the train at EVANGELISMOS Station. While in the station, take the left exit towards VAS. SOFIAS street.

Walk pass the Hilton hotel (on your left-hand side), cross Michalakopoulou Street, continue straight on Vas. Alexandrou Street. You will see DIVANI CARAVEL hotel on your right.

If you do not want to walk (approximately 5-7 minutes walk), you may take the 224 bus (the stop is across the metro station exit), and get off at “CARAVEL Bus Stop”, right in front of the hotel.

REGISTRATION FEES

Registration Categories	Online Registration	Onsite Registration
Standard	€ 500,00	€ 550,00
Participants under 35 years	€ 250,00	€ 300,00
Nurse and Data Managers	€ 200,00	€ 250,00
Exhibitors*	€ 200,00	€ 250,00

To avoid long lines at the on-site registration counters, we encourage you to register for the meeting in advance.

The registration fee includes:

- Participation in the scientific sessions
- Access to the exhibition and poster areas
- Conference kit
- Certificate of attendance
- Lunches
- Coffee breaks
- Welcome cocktail

* Exhibitor fee DOES NOT include: conference kit, participation in the scientific sessions.

REGISTRATION HOURS

Individuals and Exhibitors	
Wednesday, April 9, 2025	16.00 – 18.30
Thursday, April 10, 2025	07.30 – 18.00
Friday, April 10, 2025	08.00 – 18.00
Saturday, April 12, 2025	08.00 – 10.00

Groups	
Wednesday, April 9, 2025	16.00 – 18.30

REGISTRATION BADGES

Badges and meeting materials will be given at the counters in the registration area.

Remember to print prior and to bring with you the invitation letter and the badge QRcode you received in the “Registration Info” automatic e-mail.

All registered participants, speakers, sponsors and exhibitors will be given a badge which must be worn in order to be admitted to the scientific sessions.

Badge is mandatory to enter the congress area.

A self-printing system will be available in the Registration Area. Delegates, sponsors and exhibitors will be able to collect their badges simply by having their personal QR Code scanned by the optical reader at the self-printing machines.

Speakers are kindly requested to collect their badges at the Registration desk.

The QRcode on the badge stores the following personal information: name, surname, country and email address provided at the time of registration. It can be used by exhibitors to register visitors to their booths and to send additional information on their products and services.

CERTIFICATE OF ATTENDANCE

Delegates and speakers will be able to collect the certificate of attendance by having their personal QRcode read at the self-printing machines.

CATERING

Lunches, coffee breaks and the welcome cocktail are included in the registration fee.

You will be admitted showing your badges.

The EMN Welcome Cocktail is scheduled on Thursday, April 10, 2025 from 19.45 to 20.30 in the Congress Venue.

EXHIBITION AREA

Access to the exhibition area will be as follows.

The exhibition area will be open at the following hours:

Thursday, April 10, 2025	09.00 – 19:00
Friday, April 11, 2025	09.00 – 18:00
Saturday, April 12, 2025	09.00 – 12:00

AUDIO - VIDEO RECORDING

Audio-video recording is prohibited.

Only authorized staff can provide audio-video recording services.

OFFICIAL WEBSITE

www.emn2025.com

APP

A special mobile app has been developed for this congress.

Use the app to find sessions of interest, create your own program, find and read all the abstracts.

Download the “EMN2025” app from Apple App store or Google Play.

SCIENTIFIC INFORMATION

LANGUAGE

The meeting will be in English with no simultaneous translation into other languages.

EBAH CME CREDITS

The program of the “6th European Myeloma Network Meeting” has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 14 CME credits for Physicians, Biologists, Medical Laboratory Scientists, Nurses and Chemists. EBAH Credit Points will be awarded for the Plenary Sessions.

To request credits, please fill out the form and return it to the registration desk at the end of the meeting.

We remind you that it is necessary to have an EBAH-CME account in order to claim for credits.

Attendees can create an EBAH-CME account registering on the website: <http://ebah.org>.

SLIDE CENTER

Slide Center is located on the ground floor.

Thursday April 10, 2025	08.00 – 19.00
Friday April 11, 2025	08.00 – 18.00
Saturday April 12, 2025	08.00 – 12.00

POSTER AREA

Posters will be on display in the Poster Area for three days.

Posters should be installed/removed during the indicated set-up time:

Installation	Thursday, April 10, 2025	09.00 – 11.00
Tear off	Saturday, April 12, 2025	12.00 – 13.00

Materials to hang posters with will be available at the poster area. The Congress provides one board for each poster, the author is responsible for hanging and for removing the poster. Please note that the organisers do not take any responsibility for returning uncollected material to the authors.

MEET THE EXPERT SESSIONS

Meet the Expert Sessions take place on April 10 and April 11, 2025 during the lunch break. Registration is free of charge but **spots are limited**. Preregistration to attend these sessions is necessary. If spots are still available, you can also register onsite during registration hours.


We suggest that you do this early in order to secure your spot.

ROOM	THURSDAY, APRIL 10, 2025 12.45 - 14.00	FRIDAY, APRIL 11, 2025 12.30 - 13.45
KOZANI	IGM monoclonal gammopathies and Waldenström	Bone and renal impairment in MM
EDESSA	PCL	MM registries in real world for acceptance/reimbursement issues
NAOUSSA	CNS involvement in MM	Lab/Collaborative studies

CHANGES


Parts of the program may be changed without prior notice.

FLOOR PLAN



EXHIBITION AREA

Bristol Myers Squibb	1-2
Oncopeptides	4-5
Sebia	6
Veeda Lifesciences	7
Pfizer	8
BD	9
Johnson and Johnson	11-12
Menarini Stemline	14-15



MEZZANINE FLOOR

Meet the experts:

KOZANI

EDESSA

NAOUSSA

Meeting rooms:

MYCENEA

PELLA

PROGRAM

THURSDAY, APRIL 10, 2025

09.45-10.00 **OPENING CEREMONY**

10.00-11.00 **SESSION I:
HIGH-RISK SMM - WHEN TO START THERAPY?**

OLYMPIA



Chairpersons: J. Caers, S. Jagannath

- How to define high risk SMM? - J. Martinez-Lopez
- Do we need to treat all high risk SMM? - E.K. O'Donnell

• **B01**

PREDICTIVE VALUE OF GLUT1 EXPRESSING CIRCULATING NORMAL AND MALIGNANT PLASMA CELLS IN MULTIPLE MYELOMA

P. Tabares, V. Petit, N. Bhatnagar, A. Solimando, J. Dhanraj, A. Gonzalez-Diaz, S. Sunuwar, K. Schmiedgen, C. Cartagena, H. Dagdeviren, V. Desantis, R. Scheler-Eckstein, K.M. Kortüm, L. Rasche, J.M. Waldschmidt, P. Sonigo, C. Pinset, C. Rougé Dubroc, H. Einsele, A. Beilhack (Würzburg-DE, Paris-FR, Bari-IT, Lisses-FR)

- Panel discussion

11.00-12.45 **SESSION II:
NEW PROGNOSTIC FACTORS: MRD, CTCS, MASS SPEC,
NEW DEFINITIONS OF HIGH RISK**

OLYMPIA



Chairpersons: N. Bolli, E. Terpos

- Do we need imaging to define MRD negativity? - E. Zamagni
- CTC - L. Bertamini
- Mass Spec - N. Puig
- High risk definition - S. Trudel

• **B02**

PATHOGENESIS OF SECONDARY LEUKEMIA IN MULTIPLE MYELOMA THROUGH CAR-T INDUCED EXPANSION OF PRE-EXISTING CLONAL HEMATOPOEISIS

J.M. Waldschmidt, M. Merz, J. Hecker, F. Reinhard, B. Shibru, M. Högner, A. Gebauer, D. Fandrei, M. Meggendorfer, M. Truger, J. Jung, D. Teschner, M. Topp, A. Purcarea, V. Vucinic, K.M. Kortüm, T. Haferlach, F. Bassermann, U. Platzbecker, H. Einsele, C. Haferlach, K. Metzeler, K.S. Götze, L. Rasche (Würzburg-DE, Leipzig-DE, Munich-DE)

- Panel discussion

Debate: Genetic assessment for all patients?
(EMD, PCL, CTC and other factors vs Genetic)

Yes vs NO - A. Spencer, K.C. Weisel

Q&A and audience vote

12.45-14.00 **Lunch and meet the expert sessions on:**

1. IGM monoclonal gammopathies and Waldenström
A. Tedeschi, S. Treon

KOZANI

2. PCL

EDESSA

F. Bugge Askeland, P. Musto

3. CNS involvement in MM

NAOUSSA

G. Buda, E. Katodritou

14.00-15.30 **BRISTOL MYERS SQUIBB SPONSORED SYMPOSIUM
Innovations in multiple myeloma care: bridging gaps and
navigating relapse challenges**

OLYMPIA

Chairperson: M.A. Dimopoulos

- How first line treatment changes are impacting options at 2L+
M.A. Dimopoulos
- Patient case series: challenges and opportunities in today's practice
H. Einsele, F. Gay
- Future perspective: what is the next wave in innovation - F. Schjesvold
- Have we bridged today's treatment into tomorrow's practice -
M.A. Dimopoulos, H. Einsele, F. Gay, F. Schjesvold
- Q&A - M.A. Dimopoulos, H. Einsele, F. Gay, F. Schjesvold

15.30-16.40 **SESSION III:**

MGCS AND AMYLOIDOSIS

Chairpersons: **S. Schönland, A. Wechalekar**

- MGRS - **A. Jaccard**
- MGUS with other types of pathologies - **E. Kastritis**
- Challenges in treatment of RR amyloidosis - **P. Milani**

• B03

SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (VCD) IN NEWLY DIAGNOSED LIGHT CHAIN (AL) AMYLOIDOSIS: OVERALL SURVIVAL AND FINAL MAJOR ORGAN DETERIORATION PROGRESSION-FREE SURVIVAL (PFS) FROM THE PHASE 3 ANDROMEDA STUDY
E. Kastritis, G. Palladini, M.C. Minnema, A.D. Wechalekar, A. Jaccard, H.C. Lee, V. Santhorawala, P. Mollee J. Lu, S. Schönland, M.E. Gatt, K. Suzuki, K. Kim, M.T. Cibeira, M. Bhutani, M. Beksac, E. Libby, J. Valent, V. Hungria, M. Rosenzweig, N. Bumma, A. Huart, N. Tran, J. Wang, Y. Chen, S.Y. Vasey, J.M. Schechter, J. Vermeulen, R.L. Comenzo, G. Merlini (Athens-GR, Pavia-IT, Utrecht-NL, London-UK, Limoges-FR, Houston-USA, Boston-USA, Brisbane-AU, Beijing-CN, Heidelberg-DE, Jerusalem-IL, Tokyo-JP, Seoul-ROK, Barcelona-ES, Charlotte-USA, Ankara-TR, Seattle-USA, Cleveland-USA, São Paulo-BR, Duarte-USA, Columbus-USA, Toulouse-FR, Los Angeles-USA, Raritan-USA, Shanghai-CN, Spring House-USA, Leiden-NL)

- Panel discussion

16.40-17.10 **Coffee break and poster viewing**

17.10-18.40 **SANOFI SPONSORED SYMPOSIUM**

The road to MRD negativity: how MRD is changing practice in NDMM

Chairperson: **K. Ramasamy**

- Introduction - **K. Ramasamy**
- Lifting the roadblock: MRD- as a surrogate endpoint - **K. Ramasamy**
- Panel discussion with audience polling
- Exploring new terrain: MRD in the era of quads - **A. Broijl**
- Panel discussion with audience polling
- Navigating the journey: MRD-guided approaches in frontline therapy - **E. Zamagni**
- Panel discussion with audience polling

OLYMPIA



18.40-19.40 **SESSION IV:**

NDMM - TRANSPLANT ELIGIBLE

Chairpersons: **M. Boccadoro, P. Sonneveld**

- General overview of upfront treatment - **X. Leleu**
- Unmet needs in the era of quadruplets - do we need consolidation? - **F. Gay**
- Doublet until relapse for maintenance therapy? - **P. Sonneveld**

• B04

MODELING LONG-TERM PROGRESSION-FREE SURVIVAL IN TRANSPLANT-ELIGIBLE AND TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE

P. Sonneveld, S. Zweegman, T. Facon, V. Hungria, N. Bahlis, P. Moreau, H. Einsele, M. Boccadoro, F. Borgsten, A. Lam, M. Nobrega, V. Kovacs, J. Wang, M. Rowe, A. Sitthi-Amorn, R. Carson, M.A. Dimopoulos, P. Rodríguez-Otero, S. Usmani (Rotterdam-NL; Amsterdam-NL, Lille-FR, São Paulo-BR, Calgary-CAN, Nantes-FR, Würzburg-DE, Turin-IT, Raritan-USA, Budapest-HU, Wayne-USA, High Wycombe-UK, Athens-GR, Pamplona-ES, New York-USA)

- Panel discussion


19.40

Welcome cocktail

OLYMPIA




FRIDAY, APRIL 11, 2025

09.00-09.45 **SESSION V:**
NDMM - TRANSPLANT INELIGIBLE FIT PATIENTS 

Chairpersons: M. Beksac, R. Orłowski

- Quadruplets vs triplets in fit patients - **S. Usmani**
- Do we need continuous dexamethasone in fit patients? - **X. Leleu**
- **B05**
THE PHASE 3 CEPHEUS TRIAL OF DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH TRANSPLANT-INELIGIBLE OR TRANSPLANT-DEFERRED NEWLY DIAGNOSED MULTIPLE MYELOMA: FRAILITY SUBGROUP ANALYSIS
S. Zweegman, S. Usmani, V. Hungria, N. Bahlis, C. Venner, M. Braunstein, L. Pour, J. Marti, S. Basu, Y. Cohen, K. Suzuki, C. Hulin, S. Grosicki, W. Legiec, A. Maiolino, M. Ngo, M. Rowe, R. Carson, T. Facon (*Amsterdam-NL, New York-USA, São Paulo-BR, Calgary-CAN, Edmonton-CAN, Vancouver-CAN, Brno-CZ, Terrassa-ES, Wolverhampton-UK, Tel Aviv-IL, Tokyo-JP, Pessac-FR, Katowice-PL, Lublin-PL, Rio de Janeiro-BR, Titusville-USA, High Wycombe-UK, Wayne-USA, Lille-FR*)
- Panel discussion

09.45-10.45 **SESSION VI:**
NDMM - TRANSPLANT INELIGIBLE UNFIT AND/OR FRAIL PATIENTS 

Chairpersons: G. Cook, M. Mohty


- Dynamic frailty score - **H. Mian**
- Therapy of frail patients - **S. Zweegman**
- Is there a role for modern immunotherapy in unfit/frail patients? - **S. Manier**
- **B06**
BELANTAMAB MAFODOTIN IN COMBINATION WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN INTERMEDIATE-FIT AND FRAIL NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: THE PHASE 1/2 BELADRD STUDY
E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, N. Kanellias, P. Malandrakis, E. Solia, V. Spiliopoulou, F. Theodorakakou, M. Migkou, E. Eleutherakis-Papaiakovou, D. Fotiou, G. Psarros, E. Kastritis, M.A. Dimopoulos (*Athens-GR, Dublin-IE*)
- Panel discussion

10.45-11.00 **Coffee break and poster viewing**

11.00-11.30 **SESSION VII:**
RRMM - NON IMMUNOTHERAPY 

Chairpersons: M. Delforge, C. Driessen

- Melflufen - **F. Schjesvold**
- Selinexor - **S. Delimpasi**
- Panel discussion

11.30-12.30 **SESSION VIII:**
ANTI-BCMA TREATMENT & SEQUENCING 

Chairpersons: V. Hungria, A. Nooka

- ADC for second line - **M.A. Dimopoulos**
- Where are we with CAR-T? - **H. Einsele**
- CAR-T sequencing with other therapies - **M. Gramatzki**
- **B07**
FIRST RESULTS FROM REALITEC: A MULTI-COUNTRY OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS
K.M. Kortüm, K. Uttervall, R. Popat, S.L. Farmer, M. Cavo, B. Kishore, C. Jacquet, M. Casanova, M. Hansson, K. Weisel, H. Magen, C. Liberatore, C.T. Hansen, M.E. Gatt, T. Shragai, M.C. Da Vià, T. De Soto Alvarez, M. Streetly, M.S. Raab, S. Manier, J. Aegesen, R. Takchi, P. Hu, D. Santra, V. Strulev, E. Rubio-Azpeitia, C. Albrecht, A. Perrot (*Würzburg-DE, Stockholm-SE, London-UK, Vejle-DN, Bologna-IT, Birmingham-UK, Vandoeuvre-lès-Nancy-FR, Marbella-ES, Gothenburg-SE, Hamburg-DE, Ramat Gan-IL, Pescara-IT, Odense-DN, Jerusalem-IL, Tel-Aviv-IL, Milan-IT, Madrid-ES, Heidelberg-DE, Lille-FR, Jönköping-SE, Beirut-LB, Raritan-USA, Uxbridge-UK, Beerse-BE, Issy les Moulineaux-FR, Toulouse-FR*)
- Panel discussion

12.30-13.45 **Lunch and meet the expert sessions on:**

4. Bone and renal impairment in MM 
A. Gozzetti, A. Oriol
5. MM registries in real world for acceptance/reimbursement issues 
R. Wester, K. Yong
6. Lab/Collaborative studies 
T. Cupedo, M. D'Agostino

- 13.45-15.15 **JOHNSON AND JOHNSON SPONSORED SYMPOSIUM** OLYMPIA
Let's get clinical! Novel strategies for optimising multiple myeloma care in 2025
Chairperson: M. Delforge
- Welcome and introduction - **M. Delforge**
 - Transplant-eligible MM: are we on the brink of functional cure?
M. Delforge, P. Moreau
 - From trials to practice in RRMM: advancing the clinical use of T-cell redirecting therapies - **N. van de Donk, E. Terpos**
 - Panel Q&A - All faculty
 - Close - M. Delforge

- 15.15-16.15 **SESSION IX:
NOVEL TARGETS OF IMMUNOTHERAPY** OLYMPIA
CME
Chairpersons: M. Cavo, S. Zweegman
- Talquetamab - **Y. Cohen**
 - Bispecifics in combinations - **N. van de Donk**
 - Trispecifics - **M. Raab**
 - **B08**
TOLERABILITY AND CLINICAL ACTIVITY OF NOVEL FIRST-IN-CLASS ORAL AGENT, INOBRODIB (CCS1477), IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA
C. Pawlyn, E. Searle, V. Campbell, C. Bygrave, S. Gooding, J. Cavet, M. Jenner, V. Radhakrishnan, S. Knapper, D. El-Sharkawi, J. O'nions, T. Knurowski, K. Clegg, W. West, D. Haynes, K. Frese, T. Somerville (*London-UK, Manchester-UK, Edinburgh-UK, Cardiff-UK, Oxford-UK, Southampton-UK, Cambridge-UK*)
 - Panel discussion

- 16.15-16.45 **Coffee break and poster viewing**

- 16.45-17.45 **SPONSORED LECTURES** OLYMPIA
LECTURE 1 SPONSORED BY MENARINI STEMLINE
Optimising the sequence of novel therapies from early relapse to improve the survival of patients with relapsed/refractory multiple myeloma
E. Terpos, H. Einsele
- LECTURE 2 SPONSORED BY REGENERON**
Navigating a new frontier: exploring approaches to combining and sequencing new and old drugs in treatment of non-transplant eligible myeloma patients at diagnosis
R. Mina, C. Stege

- 17.45-18.30 **SESSION X:
MANAGEMENT OF TOXICITIES OF NEW IMMUNOTHERAPIES IN THE CLINIC** OLYMPIA
CME
Chairpersons: S. Bringhen, H. Ludwig
- CRS - **M. Merz**
 - Neurotoxicity - **E.M. Ocio San Miguel**
 - **B09**
COMPARISON OF TOXICITIES AND OUTCOMES BETWEEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY (CAR-T THERAPY) AND BISPECIFIC ANTIBODIES IN RELAPSED REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS
A. Khan, A. Butt, H. Habib, H. Kamran, A. Dad, H. Shaukat, M. Arif, H. Hameed, H. Ashfaq, F. Namal, I. Khan, M. Shahzad, N. Nguyen, M. Mushtaq, H. Fernandez (*Pembroke Pines-USA, Lahore-PK, Rahim Yar Khan-PK, Dera Ghazi Khan-PK, Faisalabad-PK, Tampa-USA, Kansas City-USA*)
 - Panel discussion

- 18.30-19.00 **SESSION XI:
PATIENT ASSOCIATIONS** OLYMPIA
CME
Chairpersons: J. Mikhael, S. ten Seldam
- International Myeloma Foundation - **J. Mikhael**
 - Myeloma Patients Europe - **S. ten Seldam**
 - Panel discussion

SATURDAY, APRIL 12, 2025

- 09.00-10.00 **EDUCATIONAL SESSION XII**
HOT TOPICS RELEVANT FOR THE MANAGEMENT OF MYELOMA PATIENTS OLYMPIA

Chairpersons: F. Gay, P. Sonneveld
- New criteria for response - J. Radocha
 - Real world data - R. Hájek
 - Tailored dose - D. Dytfeld
 - Panel discussion
- 10.00-11.00 **EDUCATIONAL SESSION XIII**
EHA-EMN JOINT SESSION: UPDATE ON EHA/EMN CLINICAL GUIDELINES OLYMPIA

Chairpersons: M. Boccadoro, H. Einsele
- First-line treatment - A. Perrot
 - Second-line treatment - E. Terpos
 - Third-line treatment and beyond - M. Gavriatopoulou
 - Panel discussion
- 11.00-11.30 **Coffee break and poster viewing**
- 11.30-12.45 **SESSION XIV:**
EMN HIGHLIGHT SESSION: CURRENT & UPCOMING TRIALS, AND FUTURE PERSPECTIVES OLYMPIA

Chairpersons: R. Hajek, E. Terpos
- Ongoing trials - A. Broijl
 - Upcoming trials - M.T. Krauth
 - Reshaping the future: the trials that we need - E.M. Ocio San Miguel
 - AI in MM - A. Mosquera
 - Panel discussion
- 12.45-13.00 **CONCLUSIONS AND FINAL GREETINGS**

POSTER

POSTER

1. BIOLOGY AND PRECLINICAL

P01

AN UNBIASED LOSS-OF-FUNCTION CRISPR-CAS9 SCREEN UNCOVERS RP11-350G8.5 AS NEW THERAPEUTIC TARGET FOR MULTIPLE MYELOMA

K. Grillone, S. Ascrizzi, P. Cremaschi, J. Amato, N. Polerà, O. Croci, R. Rocca, C. Riillo, F. Conforti, R. Graziano, D. Brancaccio, D. Caracciolo, S. Alcaro, B. Pagano, A. Randazzo, P. Tagliaferri, F. Iorio, P. Tassone (Catanzaro-IT, Milan-IT, Naples-IT, Cosenza-IT, Cambridge-UK, Philadelphia-USA)

P02

TUNNELING NANOTUBES BETWEEN BONE MARROW STROMAL CELLS SUPPORT TRANSMITOPHAGY AND RESISTANCE TO APOPTOSIS IN MYELOMA

A.G. Solimando, F. Di Palma, V. Desantis, A. Vacca, M. Svelto, F. Pisani (Bari-IT)

P03

ROLE OF SIALYLATION OF MESENCHYMAL STROMAL CELLS IN MULTIPLE MYELOMA

A. Ruer, K. Pieters, B. Stamatopoulos, N. Meuleman, L. Lagneaux (Brussels-BE)

P04

ROLE OF IGF1 AND THE IGF SYSTEM IN MULTIPLE MYELOMA: MECHANISMS OF CHEMORESISTANCE AND THERAPEUTIC IMPLICATIONS

L. Longhitano, J. Ferrigno, G. Conti, E. La Spina, E. Tropea, T. Zuppelli, S.P. Lombardo, G. Li Volti, S. Giallongo, A. Romano, F. Di Raimondo, D. Calvo, C. Giallongo, A. Liso, D. Tibullo (Catania, Enna, Catania, Perugia-IT)

P05

DEXAMETHASONE AND DARATUMUMAB IMPAIR T-CELL MEDIATED KILLING IN MULTIPLE MYELOMA: IMPLICATIONS FOR SEQUENTIAL THERAPIES

I. Dulcamare, S. Marino, N.L. Parrinello, G. Scandura, E. La Spina, D. Cambria, C. Giallongo, D. Tibullo, V. Del Fabro, C. Conticello, A. Romano, F. Di Raimondo (Catania-IT)

P06

MITOCHONDRIAL FISSION FACTOR (MFF) IS AN ACTIONABLE METABOLIC DEPENDENCY IN MULTIPLE MYELOMA

M.E. Gallo Cantafo, I. Valentino, R. Torcasio, L. Ganino, P. Murfone, E. La Spina, L. Longhitano, C. Giallongo, G. Viglietto, D. Tibullo, N. Amodio (Catanzaro, Catania-IT)

P07

TIGIT and NETOSIS: COULD THEY BE KEY PLAYERS IN MULTIPLE MYELOMA?

O. Annibali, V. Tomarchio, M.T. Tafuri, M. Dicecca, G. Maricchiolo, B. Mecorio, V. Morano, F. Arciprete, V. Velardi, M. Zingariello, A. Crescenzi, L. Rigacci (Rome-IT)

P08

PRECLINICAL EVALUATION OF ICASP9-TRANSDUCED ANTI-ROR1 CAR T-CELLS IN HEMATOLOGICAL MALIGNANCIES

D. Keyes, A. Bogdan Tigau, C. Chinde, D. Cenariu, M. Nistor, X.M. Muresan, R. Munteanu, R. Feder, D. Gulei, G. Ghiaur, C. Tomuleasa (Cluj-Napoca-RO, Baltimore-USA)

P09

CORRELATIVE RESEARCH ON PATIENTS WITH PLASMA CELL DYSCRASIAS: UPDATED ANALYSIS OF THE EMN36 INTERNATIONAL UNIFORM SAMPLE REPOSITORY

M. Van Duin, R. Hájek, G. Margiotta Casaluci, J. Minarik, P. Kessler, J. Bila, S. Morè, A. Belotti, E. Katodritou, M. Wróbel, P. Mikula, S. Palmieri, L. Stejskal, C. Terragna, L. Broskevicová, D. Oddolo, S. Aquino, I. Attucci, F. Monaco, C. Driessen, M.T. Krauth, M. Delforge, E. Terpos, L.B. Leyoldt, S. Zweegman, Y. Seok Choi, B. Bruno, A. Spencer, M. Boccaoro, P. Sonneveld, M. D'Agostino (Rotterdam-NL, Ostrava-CZ, Novara-IT, Olomouc-CZ, Pelhrimov-CZ, Belgrade-RS, Ancona-IT, Brescia-IT, Thessaloniki-GR, Nový Jičín-CZ, Havírov-CZ, Naples-IT, Opava-CZ, Bologna-IT, Genoa-IT, Florence -IT, Alessandria-IT, St. Gallen-CH, Wien-AT, Leuven-BE, Athens-GR, Hamburg-DE, Amsterdam-NL, Suwon-KR, Turin-IT, Melbourne-AUS)

P10

CLINICIANS' PERSPECTIVES AND METHODOLOGICAL APPLICATION OF FISH FOR THE DEFINITION OF CYTOGENETIC RISK IN PATIENTS WITH MULTIPLE MYELOMA: AN ITALIAN, REAL-WORLD, SURVEY-BASED REPORT FROM THE EUROPEAN MYELOMA NETWORK (EMN) ITALY

L. Cani, M.T. Petrucci, S. Morè, M. Garzia, F. Monaco, F. Pane, M. Cea, C. Cangialosi, P. Falco, L. Pettine, G.M. De Sabbata, T. Guglielmelli, D. Derudas, S. Palmieri, P. Galieni, M. Mirabile, A. Gozzetti, A. Agazzi, F. Ciambelli, M. Sessa, M. Marcatti, V. Montefusco, V. De Stefano, G.E. Parvis, F. Gherlinzoni, C. Cerchione, B. Bruno, R. Zambello, E. Zamagni, M. Boccadoro, M. D'Agostino (Turin, Rome, Ancona, Alessandria, Naples, Genoa, Palermo, Chivasso-Cirié-Ivrea, Milan, Trieste, Orbassano, Cagliari, Ascoli Piceno, Civitanova Marche, Siena, Busto Arsizio, Ferrara, Treviso, Meldola, Padua, Bologna-IT)

2. NEWLY DIAGNOSED MULTIPLE MYELOMA

P11

CLONAL HEMATOPOIESIS IS CLONALLY UNRELATED TO MULTIPLE MYELOMA AND ASSOCIATES WITH SPECIFIC MICROENVIRONMENTAL CHANGES

M. Scopetti, M. Lionetti, A. Matera, A. Maeda, A. Marella, F. Lazzaroni, G. Castellano, S. Fabris, S. Pioggia, S. Lonati, A. Marchetti, A. Cattaneo, M. Tornese, A. Neri, C. Leoni, C. De Magistris, L. Pettine, V. Traini, I. Silvestris, M. Barbieri, G. Fabbiano, D. Ronchetti, E. Taiana, M.C. Da Vià, F. Passamonti, N. Bolli (Milan, Reggio Emilia-IT)

P12

DARATUMUMAB (DARA) + BORTEZOMIB, LENALIDOMIDE AND DEXAMETHASONE (VRD) VS VRD IN TRANSPLANT-INELIGIBLE (TIE) NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) OR IF TRANSPLANT NOT PLANNED AS INITIAL THERAPY: MINIMAL RESIDUAL DISEASE ANALYSIS OF PHASE 3 CEPHEUS TRIAL

S. Zweegman, T. Facon, V. Hungria, N.J. Bahlis, C.P. Venner, M. Braunstein, L. Pour, J. Marti, S. Basu, Y.C. Cohen, M. Matsumoto, K. Suzuki, C. Hulin, S. Grosicki, W. Legiec, M. Beksac, A. Maiolino, H. Takamatsu, A. Perrot, M. Turgut, W. Liu, J. Wang, K. Chastain, J. Vermeulen, M. Krevvata, L. Lopez-Masi, J. Carey, M. Rowe, R. Carson, S.Z. Usmani (Amsterdam-NL, Lille-FR, São Paulo-BR, Calgary-CA, Edmonton-CA, Vancouver-CA, Mineola-USA, Brno-CZ, Barcelona-ES, Wolverhampton-UK, Tel Aviv-IL, Gunma-JPN, Tokyo-JPN, Pessac-FR, Katowice-PL, Lublin-PL, Ankara-TR, Rio de Janeiro-BR, Kanazawa-JPN, Toulouse-FR, Samsun-TR, Shanghai-CN, Spring House-USA, Leiden-NL, Raritan-USA, High Wycombe-UK, New York-USA)

P13

PROSPECTIVE COMPARISON OF [18F]-FDG-PET/CT AND [68GA]-GA-PSMA-PET/CT FOR STAGING OF NEWLY DIAGNOSED MULTIPLE MYELOMA

M. Talarico, M. Di Franco, I. Sacchetti, E. Manzato, S. Masci, R. Restuccia, F. Bigi, M. Puppi, M. Iezza, I. Rizzello, K. Mancuso, L. Pantani, P. Tacchetti, S. Barbato, C. Nanni, S. Fanti, M. Cavo, E. Zamagni (*Bologna-IT*)

P14

THE COMBINATION OF BELANTAMAB MAFODOTIN WITH LENALIDOMIDE AND DEXAMETHASONE IN INTERMEDIATE-FIT AND FRAIL NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA, FINAL RESULTS OF A PHASE 1/2 STUDY OF THE GREEK MYELOMA STUDY GROUP

E. Terpos, M. Gavriatopoulou, I. Ntanasis-Stathopoulos, N. Kanellias, P. Malandrakis, E. Solia, V. Spiliopoulou, F. Theodorakakou, M. Migkou, E. Eleutherakis-Papaiakovou, D. Fotiou, S. Gkolfinopoulos, E. Kastritis, M.A. Dimopoulos (*Athens-GR, Dublin-IRL*)

P15

STEM-CELL MOBILIZATION AND TRANSPLANTATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH CARFILZOMIB-LENALIDOMIDE-DEXAMETHASONE WITH OR WITHOUT ISATUXIMAB (EMN24 ISKIA TRIAL)

R. Mina, F. Gay, W. Roeloffzen, M.A. Dimopoulos, L. Rosiñol, M. Van Der Klift, A. Oriol, E. Katodritou, K.L. Wu, P. Rodriguez Otero, R. Hájek, I. Attucci, M. Van Duin, M. D'Agostino, M. Grasso, P. Ypma, S. De Jonge-Peters, J. Straub, G. Margiotta Casaluci, M. Westerman, M. Engelhardt, P. Tosi, J. Regelin, F. Schjesvold, J. Bladé, H. Einsele, P. Sonneveld, M. Boccadoro, A. Broijl (*Turin-IT, Groningen-NL, Athens-GR, Barcelona-SP, Breda-NL, Badalona-ES, Thessaloniki-GR, Antwerp-BE, Pamplona-ES, Ostrava-CZ, Florence-IT, Rotterdam-NL, Cuneo-IT, Den Haag-NL, Nijmegen-NL, Prague-CZ, Novara-IT, Alkmaar-NL, Freiburg-DE, Rimini-IT, Amersfoort-NL, Oslo-NO, Würzburg-DE*)

P16

FEASIBILITY OF MINIMAL RESIDUAL DISEASE ASSESSMENT BY NEXT GENERATION SEQUENCING IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED IN A REAL-LIFE SETTING. A 7-YEAR SINGLE-CENTER EXPERIENCE

M. Puppi, S. Armuzzi, I. Rizzello, P. Tacchetti, L. Pantani, K. Mancuso, M. Iezza, F. Bigi, M. Talarico, E. Manzato, S. Masci, R. Restuccia, I. Sacchetti, B. Taurisano, I. Vigliotta, A. Croce, M. Martello, V. Solli, S. Barbato, E. Zamagni, C. Terragna (*Bologna-IT*)

P17

PHASE 3 RANDOMIZED STUDY OF DARATUMUMAB (DARA) MONOTHERAPY VERSUS ACTIVE MONITORING IN PATIENTS (PTS) WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA (SMM): PRIMARY RESULTS OF THE AQUILA STUDY

M.A. Dimopoulos, P.M. Voorhees, F. Schjesvold, Y.C. Cohen, V. Hungria, I. Sandhu, J. Lindsay, R.I. Baker, K. Suzuki, H. Kosugi, M. Levin, M. Beksac, K. Stockerl-Goldstein, A. Oriol, G. Mikala, G. Garate, K. Theunissen, I. Spicka, A.K. Mylin, S. Bringhen, K. Uttervall, B. Pula, E. Medvedova, A.J. Cowan, P. Moreau, M.V. Mateos, H. Goldschmidt, T. Ahmadi, L. Sha, E. Rousseau, L. Li, R.M. Dennis, R. Carson, S.V. Rajkumar (*Athens-GR, Charlotte-USA, Oslo-NO, Tel Aviv-IL, São Paulo-BR, Edmonton-CA, Kent-UK, Perth-AU, Tokyo-JPN, Ogaki City-JPN, Dordrecht-NL, Ankara-TR, St. Louis-USA, Barcelona-ES, Budapest-HUN, Buenos Aires-AR, Hasselt-BE, Prague-CZ, Copenhagen-DK, Turin-IT, Stockholm-SE, Warszawa-PL, Portland-USA, Seattle-USA, Nantes-FR, Salamanca-ES, Heidelberg-DE, Plainsboro-USA, Shanghai-CN, Beersse-BE, Raritan-USA, Spring House-USA, Rochester-USA*)

P18

DARATUMUMAB (DARA)/BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE (D-VRD) WITH D-R MAINTENANCE (MAINT) IN TRANSPLANT-ELIGIBLE (TE) NEWLY DIAGNOSED MYELOMA (NDMM): ANALYSIS OF PERSEUS BASED ON CYTOGENETIC RISK

M.A. Dimopoulos, P. Sonneveld, P. Rodriguez-Otero, H. Quach, P.J. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, F. Gay, R. Mina, I.S. Nijhof, N.W.C.J. Van De Donk, E. Katodritou, F. Schjesvold, A.S. Balari, L. Rosiñol, M. Delforge, W. Roeloffzen, C. Driessen, A. Vangsted, H. Einsele, A. Spencer, R. Hajek, A. Jurczyszyn, S. Lonergan, Y. Liu, J. Wang, D. Vieyra, E.M.J. Van Brummelen, V. Vanquickenberghe, A. Sitthi-Amorn, C.J. De Boer, R. Carson, J. Bladé, M. Boccadoro, P. Moreau (*Athens-GR, Rotterdam-NL, Pamplona-ES, Melbourne-AU, Camperdown-AU, Ankara-TR, Pessac-FR, Florence-IT, Poitiers-FR, Pavia-IT, Toulouse-FR, Bologna-IT, Brescia-IT, Turin-IT, Amsterdam-NL, Nieuwegein-NL, Thessaloniki-GR, Oslo-NO, Barcelona-ES, Leuven-BE, Groningen-NL, St.Gallen-CH, Copenhagen-DK, Würzburg-DE, Ostrava-CZ, Kraków-PL, Beijing-CN, Spring House-USA, Leiden-NL, Beersse-BE, Nantes-FR*)

P19

A DETAILED IMAGING ANALYSIS ON BONE DISEASE BURDEN IN 119 NEWLY DIAGNOSED PTS WITH MULTIPLE MYELOMA

E. Terpos, V. Koutoulidis, I. Ntanasis-Stathopoulos, S. Mavropoulos-Papoudas, M. Douka, M. Gavriatopoulou, P. Malandrakis, V. Spiliopoulou, F. Theodorakakou, D. Fotiou, M. Migkou, N. Kanellias, E. Eleutherakis-Papaiakovou, E. Kastritis, L.A. Mouloupoulos, M.A. Dimopoulos (*Athens-GR*)

P20

SEQUENTIAL WHOLE BODY MAGNETIC RESONANCE IMAGING FOR EVALUATING TREATMENT RESPONSE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

I. Ntanasis-Stathopoulos, M. Douka, V. Koutoulidis, M. Gavriatopoulou, P. Malandrakis, V. Spiliopoulou, C. Filippatos, F. Theodorakakou, D. Fotiou, M. Migkou, N. Kanellias, E. Eleutherakis-Papaiakovou, I. Solia, E. Kastritis, M.A. Dimopoulos, E. Terpos, L.A. Mouloupoulos (*Athens, Heraklion-GR*)

P21

DELETION 17P, AND IGH HIGH-RISK TRANSLOCATIONS CONCURRING WITH CHROMOSOME 1 ARM ABNORMALITIES ARE THE STRONGEST PROGNOSTICATORS FOR OVERALL SURVIVAL IN THE REAL-WORLD SETTING: A VALIDATION ANALYSIS BY THE GREEK MYELOMA STUDY GROUP

E. Katodritou, E. Kastritis, D. Dalampira, I. Ntanasis-Stathopoulos, E. Spanoudakis, V. Douka, D. Fotiou, G. Kyriakidis, A. Daiou, E. Karadrakonti, X. Dimitriadou, V. Tara, K. Tsiro, T. Triantafyllou, T. Papadopoulou, C. Lalayianni, S. Delimpasi, A. Pouli, E. Verrou, M. Gavriatopoulou, M.A. Dimopoulos, E. Terpos (*Thessaloniki, Athens, Alexandroupolis-GR*)

P22

SIGNIFICANCE OF DIFFUSION-WEIGHTED WHOLE-BODY MRI (DW-MRI) IN STAGING AND RESPONSE ASSESSMENT IN MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE STUDY

A. Frolli, J. Umurungi, A. Balbo-Mussetto, N. Santoro, S. Geuna, S. Cirillo, G. Cilloni, G. Parvis (*Turin-IT*)

P23

DARATUMUMAB PLUS BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH MULTIPLE MYELOMA: A POOLED ANALYSIS OF PATIENTS AGED ≥ 65 YEARS FROM BOTH PERSEUS AND GRIFFIN STUDIES

F. Gay, P. Rodriguez-Otero, P.M. Voorhees, M. Boccadoro, J. Laubach, H. Einsele, D. Sborov, M.A. Dimopoulos, A. Broijl, R. Mina, A. Spencer, F. Schjesvold, R. Silberman, L.J. Costa, A. Perrot, Y. Liu, J. Wang, A. Sittthi-Amorn, R. Carson, A. Cortoo, S.Z. Usmani, P.G. Richardson, P. Moreau, P. Sonneveld, J.L. Kaufman (*Turin-IT, Navarra-ES, Charlotte-USA, Boston-USA, Würzburg-DE, Salt Lake City-USA, Athens-GR, Rotterdam-NL, Melbourne-AU, Oslo-NO, Portland-USA, Birmingham-USA, Toulouse-FR, Beijing-CN, Spring House-USA, Horsham-USA, New York-USA, Nantes-FR, Atlanta-USA*)

P24

REAL-LIFE ANALYSIS OF MINIMAL RESIDUAL DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ELIGIBLE FOR TRANSPLANT

I. Attucci, R. Boncompagni, C. Nozzoli, B. Peruzzi, R. Caporale, L. Pengue, M. Messeri, A.M. Vannucchi, E. Antonioli (*Florence-IT*)

P25

SECONDARY PRIMARY MALIGNANCIES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH AUTOLOGOUS STEM-CELL TRANSPLANTATION WITH OR WITHOUT MAINTENANCE WITH IMMUNOMODULATORY AGENTS: A REAL-LIFE EXPERIENCE

G. Vianello, R. Pasquale, R. Stocchi, D. Di Lorenzo, S. Buttignol, R. Mestroni, E. Favero, R. Fanin, F. Patriarca (*Udine-IT, Malakoff-FR*)

P26

FEASIBILITY AND EFFECTIVENESS OF DEXAMETHASONE-SPARING AND DOSE-REDUCTION STRATEGIES IN DARATUMUMAB-BASED REGIMENS FOR FRAIL AND SARCOPENIC NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS: A SINGLE CENTER, REAL LIFE EXPERIENCE

A. Belotti, S. Terlizzi, R. Ribolla, C. Crippa, S. Ferrari, N. Bianchetti, C. Bottelli, A. Tucci (*Brescia-IT*)

P27

DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED ≥ 80 YEARS: A MULTICENTER RETROSPECTIVE ANALYSIS OF EFFICACY AND TOLERABILITY

S. Palmieri, R. Della Pepa, S. Rocco, D. De Novellis, R. Bianco, M. Bonanni, M. Barone, G. Gaeta, A. Leone, M. Fevola, R. Fontana, M. Rizzo, M.R. Spatuzzi, M. Arcamone, N. Pugliese, C. Califano, G. Marcacci, F. Frigeri, C. Selleri, F. Pane, M. Annunziata (*Napoli, Salerno, Baronissi, Caserta, Napoli, Pagani-IT*)

P28

MRD-DRIVEN DISCONTINUATION OF LENALIDOMIDE MAINTENANCE POST TRANSPLANT IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA: A PROSPECTIVE STUDY

P. Malandrakis, I. Ntanas-Stathopoulos, I.V. Kostopoulos, V. Spiliopoulou, D. Fotiou, F. Theodorakakou, M. Migkou, N. Kanellias, E. Eleutherakis-Papaiakevou, E. Kastritis, M. Gavriatopoulou, O. Tsitsilonis, M.A. Dimopoulos, E. Terpos (*Athens-GR*)

P29

PFS2 IN THE SETTING OF PATIENTS WITH FIRST-LINE MULTIPLE MYELOMA, NOT ELIGIBLE FOR TRANSPLANT PROCEDURE AND FRAIL, ACCORDING TO BORTEZOMIB, LENALIDOMIDE AND DEXAMETASONE (VRD) SCHEDULE: EFFICACY AND SAFETY

R. Bianco (*Salerno-IT*)

P30

RENAL RESPONSE IN MULTIPLE MYELOMA TRANSPLANT ELIGIBLE PATIENTS PRESENTING WITH RENAL FAILURE IN THE ERA OF D-VTD: A REAL LIFE EXPERIENCE

V. Ruocco, I. Zatta, L. Massarotti, T. Berno, X. Hu, G. Barilà, E. Scmazzon, A. Furlan, M. Arangio Febbo, C. Clissa, R. Paolini, E. De March, L. Trentin, R. Zambello, L. Pavan (*Padua, Vicenza, Treviso, Verona, Rovigo, Belluno-IT*)

P31

SOLUBLE SERUM IL8 (sIL8) LEVELS IN MULTIPLE MYELOMA PATIENTS

A.I. Gkioka, M.T. Tryfou, A. Gkiokas, G. Oikonomou, A. Koudouna, V. Bartzis, M.C. Kyrtsonis (*Athens-GR*)

P32

SOLUBLE SERUM FAS LIGAND (sFasL) LEVELS IN MULTIPLE MYELOMA PATIENTS

A.I. Gkioka, A. Gkiokas, M.T. Tryfou, G. Oikonomou, A. Koudouna, V. Bartzis, M.C. Kyrtsonis (*Athens-GR*)

P33

LOW VACCINATION RATES AGAINST SEASONAL INFLUENZA AND PNEUMONIA IN MGUS AND MM PATIENTS AFTER COVID-19 PANDEMICS: A REAL-LIFE SURVEY

A. Romano, M. Aiello, M. Khosropoor, A. Bulla, M. La Morella, C. Bellofiore, A. Curtopelle, V. Del Fabro, U. Markovic, F. Puglisi, R. Ragusa, F. Di Raimondo, C. Conticello (*Catania-IT*)

P34

LONG SURVIVAL WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE IN NTE-NDMM PATIENTS. A SURVEY OF TWO HEMATOLOGICAL CENTERS

V. Del Fabro, G. Giunta, L. Gullo, G. Uccello, C. Bellofiore, C.M.C. Sorbello, C. Lo Faro, D. Leotta, F. Lo Presti, F. Elia, A. Romano, F. Di Raimondo, C. Conticello (*Enna, Catania-IT*)

P35

ADDITION OF DARATUMUMAB TO FIRST-LINE THERAPY OF NEWLY DIAGNOSED MULTIPLE MYELOMA IN PATIENTS ELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE-CENTER EXPERIENCE

E. Olivari, L. Paris, P. Stefanoni, C. Pavoni, A. Rambaldi, M. Galli (*Milan, Bergamo-IT*)

P36

REAL-LIFE EXPERIENCE WITH FIRST-LINE TREATMENT WITH DARATUMUMAB-BASED THERAPY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA INELIGIBLE FOR AUTOLOGOUS STEM-CELL TRANSPLANTATION

F. Fazio, E. Amabile, M. Capriata, C. Lisi, A. Piciocchi, M. Antonacci, M. Totaro, M. Martelli, M.T. Petrucci (*Rome-IT*)

P37

FIRST-LINE DARATUMUMAB-BASED REGIMENS WITH OR WITHOUT AUTOLOGOUS STEM-CELL TRANSPLANTATION IN MULTIPLE MYELOMA PATIENTS AGED 65-70: A REAL-WORLD STUDY ON EFFICACY AND SAFETY

S. Palmieri, R. Della Pepa, S. Rocco, M. Bonanni, C. Masucci, D. De Novellis, M. Barone, R. Bianco, G. Delle Cave, A. Lucania, G. Gaeta, R. Reina, A. Leone, M. Arcamone, R. Fontana, M. Rizzo, N. Pugliese, C. Califano, C. Selleri, A.M. Risitano, G. Marcacci, F. Pane, M. Annunziata (*Napoli, Avellino, Salerno, Baronissi, Pagani, Caserta, Giugliano in Campania-IT*)

P38

NEGATIVE IMPACT OF HIGH SERUM CREATININE AND LACTATE DEHYDROGENASE AT DIAGNOSIS CAN BE OVERCOME BY AUTOLOGOUS STEM CELL TRANSPLANTATION

M.D. Yucedag, S. Bulut, T.K. Yucedag, P.M. Akbay, S.K. Toprak, M. Kurt Yuksel, P. Topcuoglu, O. Arslan, M. Ozcan, T. Demirer, M. Beksac, G. Cengiz Seval (Ankara-TR)

P39

CIRCULATING TUMOR CELLS - NEW PROGNOSTIC BIOMARKER IN MULTIPLE MYELOMA

A. Sretenovic, M. Mitrovic, N. Kraguljac Kurtovic, Z. Bukumiric, J. Bila (Belgrade-RS)

3. RELAPSED/REFRACTORY MULTIPLE MYELOMA**P40**

OVERALL SURVIVAL (OS) WITH CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VERSUS STANDARD OF CARE (SOC) IN LENALIDOMIDE (LEN)-REFRACTORY MULTIPLE MYELOMA (MM): PHASE 3 CARTITUDE-4 STUDY UPDATE

X. Leleu, J. San-Miguel, M.V. Mateos, B. Dhakal, C. Touzeau, N.W.C.J. van de Donk, S. Sidana, A. Oriol, Y.C. Cohen, S.J. Harrison, H. Einsele, P. Corradini, D. Chen, Q. Li, K. Li, A. Slaughter, C. Lonardi, N. Benachour, M. Vogel, N. Lendvai, M. Koneru, N. Patel, E. Florendo, P.J. Ho, R. Popat (Poitiers-FR, Pamplona-ES, Salamanca-ES, Milwaukee-USA, Nantes-FR, Amsterdam-NL, Stanford-USA, Barcelona-ES, Tel Aviv-IL, Melbourne-AU, Parkville-AU, Würzburg-DE, Milan-IT, Shanghai-CN, Apex-USA, Spring House-USA, Zug-CH, Buenos Aires-AR, Beerse-BE, Neuss-DE, Raritan-USA, Somerset-USA, Sydney-AU, London-UK)

P41

CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VS STANDARD OF CARE (SOC) IN PATIENTS WITH LENALIDOMIDE (LEN)-REFRACTORY MULTIPLE MYELOMA (MM) AFTER 1-3 LINES OF THERAPY: MINIMAL RESIDUAL DISEASE NEGATIVITY (MRD-NEG) IN THE PHASE 3 CARTITUDE-4 TRIAL

A. Oriol, R. Popat, M. Cavo, L. Karlin, I. Avivi, W. Roeloffzen, S.J. Kim, B. Lipe, N. Bar, N. Horvath, A. Spencer, C.K. Min, D. Chen, Q. Li, K. Li, A. Slaughter, C. Lonardi, N. Benachour, A. Ghosh, M. Vogel, N. Lendvai, T. Lengil, N. Patel, O.C. Filho, E. Florendo, Y. Lin (Barcelona-ES, London-UK, Bologna-IT, Pierre-Bénite-FR, Tel Aviv-IL, Groningen-NL, Seoul-ROK, Rochester-USA, New Haven-USA, Adelaide-AU, Melbourne-AU, Shanghai-CN, Apex-USA, Spring House-USA, Zug-CH, Buenos Aires-AR, Beerse-BE, Raritan-USA, Neuss-DE, Somerset-USA, Rochester-USA)

P42

BELANTAMAB MAFODOTIN+BORTEZOMIB+DEXAMETHASONE (BVD) VS DARATUMUMAB+VD (DVD) IN RRMM: UPDATES ON OVERALL SURVIVAL (OS) AND EFFICACY IN DREAMM-7

M. Dimopoulos, V. Hungria, P. Robak, M. Hus, V. Zherebtsova, C. Ward, P. Ho, R. Hajek, K. Kim, S. Grosicki, H. Sia, A. Bryant, M. Lacerda, G. Martinez, A. Balarí, I. Sandhu, C. Cerchione, P. Ganly, C. Fu, M. Garg, A.O. Abdallah, M. Gatt, A. Oriol, M. Cavo, R. Rifkin, T. Fujisaki, M. Mielnik, N. Pirooz, J. Lee, A. Mckeown, R. Rogers, H. Baig, L. Eccersley, S. Roy-Ghanta, J. Opalinska, M.V. Mateos (Athens-GR, São Paulo-BR, Łódź-PL, Lublin-PL, Moscow-RU, Sydney-AU, Camperdown-AU, Ostrava-CZ, Seoul-KR, Katowice-PL, Gold Coast-AU, Sydney-AU, Joinville-BR, São Paulo-BR, Barcelona-ES, Edmonton-CA, Meldola-IT, Christchurch-NZ, Jiangsu-CN, Leicester-UK, Fairway-USA, Jerusalem-IL, Badalona-ES, Bologna-IT, Denver-USA, Matsuyama-JP, Upper Providence-USA, London-UK, Stevenage-UK, Mississauga-CA, Salamanca-ES)

P43

EFFECTIVENESS OF BRIDGING THERAPY CORRESPONDS TO IMPROVED OUTCOMES AFTER RECEIVING CAR-T THERAPY: PHASE 3 CARTITUDE-4 STUDY OF PATIENTS WITH RELAPSED, LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA

L. Karlin, S. Anguille, X. Leleu, M. Gatt, A. Spencer, S. Iida, T. Ishida, Y. Lin, C.K. Min, S.J. Kim, A. Slaughter, C. Lonardi, N. Benachour, M. Vogel, V. Plaks, K. Li, D. Chen, Q. Li, T. Lengil, M. Koneru, N. Patel, O.C. Filho, S.J. Harrison, J. San-Miguel, H. Einsele (Pierre-Bénite-FR, Edegem-BE, Poitiers-FR, Jerusalem-IL, Melbourne-AU, Nagoya-JP, Tokyo-JP, Rochester-USA, Seoul-KR, Zug-CH, Buenos Aires-AR, Beerse-BE, Neuss-DE, Raritan-USA, Spring House-USA, Shanghai-CN, Apex-USA, Somerset-USA, Parkville-AU, Pamplona-ES, Würzburg-DE)

P44

EFFICACY AND SAFETY OF WEEKLY SELINEXOR, IN COMBINATION WITH POMALIDOMIDE, AND DEXAMETHASONE (SPd) FOR TREATMENT OF PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATES FROM THE STOMP TRIAL

M. Baljevic, N. Bahlis, R. Kotb, G. Schiller, B. Lipe, S. Madan, H. Sutherland, S. Lentzsch, N. Callander, N. Biran, D. Van Domelen, T. Mark, D. White (Tennessee-USA, Alberta-CA, Manitoba-CA, California-USA, New York-USA, Arizona-USA, British Columbia-CA, Wisconsin-USA, New Jersey-USA, Massachusetts-USA, Nova Scotia-CA)

P45

THE TREATMENT OF PATIENTS PROGRESSING AFTER LENALIDOMIDE MAINTENANCE: AN ITALIAN REAL-LIFE STUDY OF 284 CASES.

G. Barilà, V. Ruocco, C. Liberatore, E. Olivari, M. Tinelli, F. Fazio, S. Morè, E. Favero, C.S. Cartia, N. Sgherza, C. Conticello, R. Mina, M. Gherardini, G. Mele, M. Gentile, A. Furlan, M.A. Febbo, O. Annibali, B. Rossini, E. Scomazzon, E.A. Martino, C. De Magistris, F. Fioritoni, A.M. Cafro, S. Pezzatti, R. Della Pepa, P. Boggione, G. Pietrantuono, V. Tomarchio, F. Vassallo, M.L. Pioltelli, F. Pisani, A. Cagnetta, E. Antonioli, L. Paris, A. Tosetto, P. Musto, E. Zamagni, F. Patriarca, S. Mangiacavalli, R. Zambello, M. Offidani, M.T. Petrucci (Vicenza, Padua, Pescara, Bergamo, Verona, Rome, Ancona, Udine, Pavia, Bari, Catania, Turin, Brindisi, Cosenza, Treviso, Milan, Monza, Naples, Novara, Rionero in Vulture, Cuneo, Genoa, Florence, Bologna-IT)

P46

EFFICACY OUTCOMES BY MINIMAL RESIDUAL DISEASE NEGATIVITY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA TREATED WITH BELANTAMAB MAFODOTIN+BORTEZOMIB+DEXAMETHASONE VS DARATUMUMAB+BORTEZOMIB+DEXAMETHASONE: ANALYSIS FROM THE DREAMM-7 TRIAL

M. Dimopoulos, V. Hungria, M. Hus, P. Robak, V. Zherebtsova, A. Ribas, M. Lacerda, K. Kim, S. Grosicki, I. Sandhu, C. Ward, A. Mckeown, H. Baig, J. Ma, B. Lariviere, B. Kazeem, L. Eccersley, S. Roy-Ghanta, J. Opalinska, M.V. Mateos (Athens-GR, São Paulo-BR, Lublin-PL, Lodz-PL, Moscow-RU, Florianópolis-BR, Joinville-BR, Seoul-KR, Katowice-PL, Edmonton-CA, Sydney-AU, Stevenage-UK, Mississauga-CA, Waltham-USA, London-UK, Upper Providence-USA, Philadelphia-USA, Salamanca-ES)

P47

EFFICACY OF IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR CENTRAL NERVOUS SYSTEM MANIFESTATION: A MULTICENTER REAL-WORLD ANALYSIS

M. Maulhardt, S. Call, H. Boyadzhiev, A.M. Albici, K. Hörster, A. Boquoi, S. Janjetovic, A.O. Saidy, M. Teichert, A. Brioli, C. Schultze-Florey, F. Heidel, P. Schindler, N. Schub, E. Aydilek, M. Stelljes, M. Daskalakis, C. Krekeler, J. Hasenkamp, C. Khandanpour, U. Bacher, H.C. Reinhardt, G. Lenz, F. Stölzel, T. Pabst, B. Von Tresckow, G. Wulf, P. Berning, E. Shumilov (Goettingen, Muenster, Bern, Kassel, Kiel, Essen, Berlin, Hannover, Bielefeld, Luebeck-DE)

P48

LONG-TERM BENEFITS IN PATIENT (PT)-REPORTED OUTCOMES AND TIME TO NEXT THERAPY (TTNT) OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) VS STANDARD OF CARE (SOC) FOR PTS WITH LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA (MM): RESULTS FROM THE PHASE 3 CARTITUDE-4 TRIAL

K. Weisel, N. Bar, R. Mina, A.K. Mylin, H. Yokoyama, H. Magen, W. Alsdorf, M.C. Minnema, L. Shune, I. Isufi, S.J. Harrison, U.A. Shah, A. De Champlain, K.S. Gries, D. Chen, Q. Li, T.M. Yeh, A. Slaughter, C. Lonardi, N. Benachour, A. Ghosh, W. Deraedt, M. Vogel, N. Lendvai, N. Patel, O.C. Filho, E. Florendo, L. Karlin (Hamburg-DE, New Haven-USA, Turin-IT, Copenhagen-DK, Sendai-JP, Petach Tikva-IL, Utrecht-NL, Kansas City-USA, Melbourne-AU, Parkville-AU, New York-USA, Horsham-USA, Raritan-USA, Shanghai-CN, Apex-USA, Zug-CH, Buenos Aires-AR, Beerse-BE, Neuss-DE, Somerset-USA, Pierre-Bénite-FR)

P49

CLINICAL EFFICACY OF ISATUXIMAB PLUS CARFILZOMIB -DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: UPDATE OF A REAL-LIFE MULTI-CENTER RETROSPECTIVE EXPERIENCE

D. De Novellis, D. Derudas, D. Vincelli, R. Fontana, R. Della Pepa, S. Palmieri, F. Accardi, F. Rotondo, E. Morelli, E. Gigliotta, D. Roccotelli, L. Marano, M.L. Barone, G. Cetani, D. Esposito, A. Lazzaro, G. Delle Cave, B. Serio, D. Morini, M. Porrizzo, E. Urciuoli, C. Masucci, F. Fanelli, M. Rizzo, M. Arcamone, F. Trastulli, S. Rocco, A. Leone, R. Bianco, F. Salvatore, A. Idato, M. Sicari, P. Tosi, M.G. Rascato, M. Di Perna, A.P. Falcone, L. Morello, M. Carlisi, G. Svanera, M. Annunziata, F. Frigeri, C. Califano, A.M. Carella, G. Marcacci, F. Pane, A.M. Risitano, V. Giudice, C. Botta, C. Selleri (Salerno, Baronissi, Cagliari, Reggio Calabria, Napoli, Palermo, Rimini, San Giovanni Rotondo, Avellino, Pagani, Caserta, Aversa, Piacenza, Giugliano in Campania-IT)

P50

LINVOSELTAMAB IN PATIENTS IDENTIFYING AS BLACK OR AFRICAN AMERICAN WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM LINKER-MM1

J. Zonder, J. Richter, S. Jagannath, H. Lee, A. Suvannasankha, J. Hoffman, M. Shah, S. Lentzsch, N. Bumma, R. Baz, S. Namburi, K. Wu, J. Maly, R. Silbermann, C. Min, M. Pianko, M. Vekemans, M. Munder, J. Byun, J. Martínez-López, M. Deveaux, D. Chokshi, M. Seraphin, K. Knorr, G. Kroog, M. Dhodapkar (Detroit-USA, New York-USA, Houston-USA, Indianapolis-USA, Miami-USA, New Brunswick-USA, Columbus-USA, Tampa-USA, Seattle-USA, Antwerp-BE, Louisville-USA, Portland-USA, Seoul-KOR, Ann Arbor-USA, Brussels-BE, Mainz-DE, Madrid-ES, Tarrytown-USA, Atlanta-USA)

P51

A PROSPECTIVE, OBSERVATIONAL STUDY OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH IXAZOMIB IN REAL-WORLD SETTINGS IN GREECE: THE 'OL-ORAL' STUDY

E. Katodritou, M.C. Kyrtsonis, S. Delimpasi, E. Spanoudakis, G. Vassilopoulos, P. Zikos, N. Viniou, G. Kaiafa, M. Papathanasiou, V. Pappa, E. Michalis, I. Adamopoulos, K. Kokoviadou, G. Tsirakis, C. Poziopoulos, E. Mantouvalou, E. Tentzera, E. Terpos (Thessaloniki, Athens, Alexandroupoli, Larissa, Patras, Kalamata, Chania-GR)

P52

EFFICACY AND SAFETY OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE (ISAKD) IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION AND LENALIDOMIDE MAINTENANCE: RESULTS FROM THE REAL-LIFE AENEID STUDY

N. Sgherza, P. Curci, O. Battisti, C. Conticello, M. Gentile, S. Palmieri, C. Germano, G. Mele, D. Derudas, F. Fazio, R. Della Pepa, A. Mele, S. Rasola, B. Rossini, G. Palazzo, D. Roccotelli, F. Pane, M.T. Petrucci, F. Di Raimondo, E. Resta, P. Musto (Bari, Catania, Cosenza, Rende, Napoli, Barletta, Brindisi, Cagliari, Rome, Tricase, Taranto, San Giovanni Rotondo-IT)

P53

EVALUATION OF ATTRITION RATES IN REAL-LIFE SETTING: A SINGLE-CENTER SURVEY IN THE LAST 12 YEARS (2012-2024)

A. Romano, M. Khosropoor, G. Santuccio, C. Bellofiore, O. Bianco, V. Leotta, V. Del Fabro, F. Elia, F. Di Raimondo, C. Conticello (Catania-IT)

P54

CLINICAL OUTCOMES AND SAFETY OF DARATUMUMAB POMALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS TREATED IN AN ITALIAN REAL-LIFE MULTICENTER RETROSPECTIVE STUDY

R. Bianco, D. Derudas, D. Roccotelli, S. Palmieri, S. Rocco, G. Delle Cave, A. Amendola, M. Barone, R. Iula, D. Esposito, R. Della Pepa, A. Leone, R. Fontana, D. De Novellis, C. Botta, C. Masucci, M. Bonanni, M.R. Spatuzzi, G. Svanera, G.R. Nunziata, G. Marcacci, M. Pizzuti, A.M. Carella, A.M. Risitano, F. Pane, C. Selleri, C. Califano, M. Annunziata, F. Frigeri (Caserta, Cagliari, San Giovanni Rotondo, Napoli, Giugliano In Campania, Potenza, Pagani, Aversa, Palermo, Avellino-IT)

P55

OUTCOMES OF SECOND-LINE THERAPY IN FUNCTIONAL HIGH-RISK MULTIPLE MYELOMA PATIENTS REFRACTORY TO QUADRUPLLET INDUCTION: A MULTI-CENTER REAL-LIFE STUDY

D. De Novellis, R. Fontana, R. Della Pepa, S. Palmieri, S. Rocco, D. Derudas, D. Roccotelli, D. Esposito, C. Masucci, E. Gigliotta, M.L. Barone, E. Morelli, A. Lazzaro, R. Bianco, F. Accardi, L. Marano, M. Bonanni, B. Serio, E. Urciuoli, M. Rizzo, M. Arcamone, R. Iula, A. Dandolo, A. Leone, M.G. Rascato, M. Di Perna, A.P. Falcone, L. Morello, G.R. Nunziata, G. Marcacci, F. Frigeri, C. Califano, A.M. Carella, A.M. Risitano, M. Annunziata, F. Pane, V. Giudice, C. Botta, C. Selleri (Salerno, Baronissi, Napoli, Cagliari, San Giovanni Rotondo, Aversa, Avellino, Palermo, Pagani, Piacenza, Caserta-IT)

P56

SUPPORTING TREATMENT DECISION-MAKING FOR LENALIDOMIDE-REFRACTORY MULTIPLE MYELOMA PATIENTS POST-DRD IN ITALY: A MULTI-CRITERIA DECISION FRAMEWORK

M. Boccadoro, A. Belotti, F. Bombaci, S. Bringham, G. Buda, A.M. Cafro, M. Caimmi, B. Canali, P.L. Canonico, M. Cavo, A. Corso, L. De Paoli, D. Derudas, F. Di Raimondo, C. Galeone, F. Gay, M. Gentile, N. Giuliani, P. La Malfa, R. Mercati, V. Montefusco, P. Musto, M. Offidani, F. Patriarca, M.T. Petrucci, M. Riccaboni, P. Tosi, E. Zamagni, R. Zambello, F. Fiorentino (Turin, Brescia, Pisa, Milan, Novara, Bologna, Legnano, Vercelli, Cagliari, Catania, Cosenza, Parma, Bari, Ancona, Udine, Rome, Lucca, Rimini, Padua-IT)

P57

FROM SPAIN TO THE WORLD: EXPERIENCE WITH TALQUETAMAB AS MONOTHERAPY IN RRMM PATIENTS OUTSIDE CLINICAL TRIALS, THE BITAL STUDY.

M.J. Blanchard, E. Fernández Poveda, E. Lavilla Rubira, C. López-Santamaría Castro, P. Lorente Alegre, J.M. Sánchez Pina, M. González-Pardo, P. Rodríguez-Otero, M.V. Mateos (*Madrid, Cartagena, Lugo, Badajoz, Valencia, Navarra, Salamanca-SP*)

P58

PREVALENCE AND PROGNOSTIC SIGNIFICANCE OF FUNCTIONAL HIGH RISK MULTIPLE MYELOMA IN TRANSPLANT ELIGIBLE PATIENTS: A REAL LIFE EXPERIENCE

V. Simeon, E. Favero, G. Facchin, M. De Martino, R. Stocchi, M. Isola, R. Fanin, F. Patriarca (*Udine-IT*)

P59

REAL-WORLD BISPECIFIC ANTIBODY THERAPY FOR MULTIPLE MYELOMA: INSIGHTS FROM DUTCH NATIONWIDE REGISTRY

M. Appelman, R. Oostvogels, A. Broijl, L. Franssen, P. Geerts, E. Van Der Spek, H. De Lil, C. Van Rooijen, P. Ypma, W. Roeloffzen, J. Van Elsen, E. De Korte, K. Groen, I. Nijhof, R. Wester (*Rotterdam, Utrecht, 's-Hertogenbosch, Zwolle, Arnhem, Eindhoven, Enschede, Den Haag, Groningen, Maastricht, Nijmegen, Amsterdam, Nieuwegein-NL*)

P60

COMPARISON OF ISATUXIMAB-POMALIDOMIDE-DEXAMETHASONE VERSUS ELOTUZUMAB-POMALIDOMIDE-DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A TARGET TRIAL EMULATION USING REAL-WORLD DATA

E.A. Martino, A. Pitino, M. Offidani, R. Della Pepa, A. Gozzetti, V. Bongarzone, A. Maroccia, V. Amico, P. Stefanoni, E. Zamagni, S. Terlizzi, D. Derudas, S. Palmieri, R. Bianco, C. Conticello, M. Brunori, A. Rago, F. Lotti, R. Fontana, N. Sgherza, E. Rossi, A.M. Cafro, M. Arangio Febbo, A.M. Quinto, C. Cerchione, G. Margiotta Casaluci, A. Citro, C. Califano, R. Zambello, S. Mangiacavalli, C. Liberatore, G. Buda, C. De Magistris, A. Amendola, E. Vigna, A. Bruzzese, E. Barbieri, M. Quaresima, D. Roccotelli, F. Farina, J. Micozzi, I.D. Vincelli, G. Tarantini, E. Antonioli, S. Aquino, A. Maggi, A. Lombardo, G. Bertuglia, A. Furlan, A. Mele, O. Annibaldi, E. Cotzia, P. Benvenuti, L. De Paoli, G. Barilà, S. Morè, V. De Stefano, F. Di Raimondo, M.T. Petrucci, N. Bolli, P. Musto, A. Neri, F. Morabito, G. Tripepi, M. Gentile (*Cosenza, Rome, Ancona, Naples, Siena, Venice-Mestre, Benevento, Bergamo, Bologna, Brescia, Cagliari, Caserta, Catania, Fano, Perugia, Salerno, Bari, Milan, Padua, Meldola, Forlì-Cesena, Novara, Legnano, Pagani, Pavia, Pescara, Chieti, Pisa, Potenza, Reggio Emilia, Modena, San Giovanni Rotondo, Reggio Calabria, Barletta, Florence, Genoa, Taranto, Terni, Turin, Treviso, Tricase, Siracusa, Varese, Vercelli, Vicenza, Rende-IT*)

P61

EFFICACY AND TOLERABILITY OF MELFLUFEN IN RELAPSED MULTIPLE MYELOMA, A SINGLE CENTER REAL LIFE EXPERIENCE

G. Giunta, E. Longo, C. Lo Faro, G. Lavenia, V. Del Fabro, F. Elia, A. Romano, F. Di Raimondo, C. Conticello (*Catania, Enna-IT*)

P62

REAL-WORLD ANALYSIS OF TECLISTAMAB TREATMENT FOR RELAPSED REFRACTORY MULTIPLE MYELOMA IN TWO BELGIAN UNIVERSITY HOSPITALS

N. Meuleman, G. Jadot, W. Smits, M. Vercruyssen, O. Rizzo, M.C. Vekemans (*Brussels-BE*)

P63

REAL-LIFE DATA ON SAFETY AND EFFICACY OF AUTOLOGOUS STEM CELL TRANSPLANTATION IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA

S. Bulut, D. Yücedağ, P. Akbay, K. Yücedağ, S.K. Toprak, M.K. Yüksel, P. Topçuoğlu, O. Arslan, M. Ozcan, T. Demirer, M. Beksaç, G. Cengiz Seval (*Ankara-TR*)

P64

DEXAMETHASONE, CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (DCEP) AS A SALVAGE OPTION IN THE ERA OF NOVEL AGENTS: A SINGLE CENTER REAL LIFE EXPERIENCE

E. Longo, M. Schinocca, G. Giunta, C. Lo Faro, V. Del Fabro, G. Moschetti, G. Milone, F. Elia, A. Romano, F. Di Raimondo, C. Conticello (*Catania, Enna-IT*)

P65

IS IT TIME TO FIGHT MULTI-REFRACTORINESS IN PATIENTS WITH FIRST RELAPSE IN MULTIPLE MYELOMA IN ITALY?

S. Morè, V.M. Manieri, L. Corvatta, F. Mostardi, E. Morsia, A. Poloni, M. Offidani (*Ancona, Fabriano-IT*)

P66

MASS SPECTROMETRY (MALDI-TOF) IS MORE INFORMATIVE THAN IMMUNOFIXATION ANALYSIS IN REFERENCE TO BONE MARROW FLOW CYTOMETRIC MEASURABLE RESIDUAL DISEASE (FLOW-MRD) ASSESSMENT IN MULTIPLE MYELOMA

E. Vural, H. Aytakin, M. Aydoğan, G. Cengiz Seval, R. Öcal, O. Nevruz, A.T. Baykal, K. Dalva, M. Beksaç (*Ankara, Istanbul-TR*)

4. SPECIAL CONDITIONS

P67

A REAL-WORLD RETROSPECTIVE-PROSPECTIVE ANALYSIS OF SECONDARY IMMUNODEFICIENCY AND RISK OF INFECTION IN PATIENTS WITH AL AMYLOIDOSIS TREATED WITH DARATUMAMAB-BASED INDUCTION REGIMENS. A MULTICENTER ITALIAN EXPERIENCE

A. Furlan, V. Carabotta, T. Berno, L. Pavan, R. Zambello, S. Morè, M. Offidani, F. Di Landro, E. Rossi, L. Paris, A. Cagnetta, C. Conticello, F. Guidotti, E. Agostani, R. Ria, M. Arangio Febbo, M. Capriata, F. Fazio, E. De March, M. Tinelli, N. Rabassi, S. Vedovato, V. Venanzi, A. Gozzetti, L. Pettine, M. Da Via, S. Conca, E. Sbisà, S. Mangiacavalli, C. Cartia, A. Maroccia, E. Martino, M. Gentile, R. Paolini, S. Girlanda, A. Dell'Edera, C. Piovesan, F. Gherlinzoni (*Treviso, Padua, Ancona, Rome, Bergamo, Genoa, Catania, Como, Bari, Belluno, Verona, Bolzano, Vicenza, Siena, Milan, Vittorio Veneto, Trieste, Pavia, Venice-Mestre, Cosenza, Rovigo-IT*)

P68

VENOUS THROMBOEMBOLISM RISK SCORES IN PATIENTS WITH MULTIPLE MYELOMA RECEIVING DARATUMAMAB, LENALIDOMIDE, AND DEXAMETHASONE

C. Liberatore, M. Candeloro, F. Fioritoni, N. Potere, S. Ciavarella, D. Tuosto, S. Pulini, E. Porreca, M. Di Nisio, M. Di Ianni (*Pescara, Chieti-IT*)

P69

OBSERVATION OR TREATMENT FOR SMOLDERING MULTIPLE MYELOMA? A SYSTEMATIC REVIEW AND META-ANALYSIS OF RANDOMIZED CONTROLLED STUDIES

I. Ntanasis-Stathopoulos, C. Filippatos, P. Malandrakis, E. Kastiris, E. Terpos, M.A. Dimopoulos, M. Gavriatopoulou (Athens-GR)

P70

MORTALITY RATE OF PATIENTS WITH MAYO STAGE IV AL AMYLOIDOSIS IN PHASE 3 VITAL TRIAL PLACEBO ARM IS REPRESENTATIVE OF REAL-WORLD MORTALITY PER MATCHED MAYO CLINIC COHORT

A. Dispenzieri, E. Muchtar, S. Kumar, D. Dingli, S. Hayman, P. Kapoor, T. Kourelis, N. Leung, R. Warsame, Y.L. Hwa, A. Fonder, M. Hobbs, C. Karp, I. Sprinz, C. Nie, M.A. Gertz (Rochester, Brisbane-USA)

P71

DARATUMUMAB-BASED TREATMENTS IN STAGE IIIB AL AMYLOIDOSIS: REAL LIFE EXPERIENCE FROM ANCONA TERTIARY CENTER

S. Morè, V.M. Manieri, L. Corvatta, F. Guerra, A. Ranghino, M. Valente, E. Morsia, A. Poloni, M. Offidani (Ancona, Fabriano-IT)

P72

POSITIVE IMPACT OF BOTH ENZYME REPLACEMENT AND SUBSTRATE REDUCTION THERAPY ON MGUS IN TWO PATIENTS WITH GAUCHER DISEASE

U. Markovic, S. Grasso, V. Vecchio, C. Conticello, A. Romano, V. Del Fabro, F. Di Raimondo, G. Giuffrida (Catania-IT)

P73

VACCINATION STRATEGIES AND ANTIMICROBIAL PROPHYLAXIS IN PATIENTS WITH MULTIPLE MYELOMA: A REAL-WORLD PRACTICE SURVEY AMONG EMN-ITALY CENTERS

O. Annibali, G. Barilà, C. Clissa, D. Vincelli, D. Derudas, B. Rossini, F. Guidotti, S. Bringhen, E. Zamagni, M. Boccadoro, M.T. Petrucci (Rome, Vicenza, Pesaro, Reggio Calabria, Cagliari, Bari, Como, Turin, Bologna-IT)

P74

TREATMENT PATTERNS OF BONE-TARGETED AGENTS FOR THE PREVENTION OF SKELETAL-RELATED EVENTS IN MULTIPLE MYELOMA IN BULGARIA: A CROSS-SECTIONAL CHART REVIEW STUDY

G. Mihaylov, V. Ianakieva, Z. Katrandzhieva, K. Karaasenov, V. Goranova-Marinova (Sofia, Plovdiv-BG)

P75

CYTOMEGALOVIRUS INFECTION AFTER AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA EXPOSED TO DARATUMUMAB

C. Liberatore, M. D'Uva, A. Natale, F. Guardalupi, L. Di Re, F. Fioritoni, S. Pulini, R. Spadano, D. Vaddinelli, S. Santarone, M. Di Ianni (Pescara, Chieti-IT)

P76

SAFETY OF DECADE PLUS USE OF IGPRO20 IN THE REAL WORLD: POST-MARKETING PHARMACOVIGILANCE REPORT

A. Radu, C. Sawyer, A. Hubsch, V. Katkade (Marburg-DE, Melbourne-AU, Bern-CH, King of Prussia-USA)

ACKNOWLEDGEMENTS

With an unrestricted educational grant of

PLATINUM SPONSOR



Johnson & Johnson

sanofi

GOLD SPONSOR



Stemline[®]
A Menarini Group Company

REGENERON
SCIENCE TO MEDICINE[®]

SILVER SPONSOR

AMGEN



Pfizer
Oncology

Veeda[™]
Lifesciences

CONTRIBUTORS

BECTON DICKINSON

ONCOPEPTIDES

PAREXEL

SEBIA

TAKEDA